Navigation Links
DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
Date:4/9/2013

San Diego, CA (PRWEB) April 09, 2013

The drug safety advocates at DrugRisks.com are alerting of updated legal news on the site for patients who have taken the diabetes drug Actos. Trial continues against the maker of the drug for a man alleging it caused his terminal bladder cancer***.

DrugRisks is designed to improve the safety of those taking popular prescription drugs like Actos by providing the latest warnings, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice.

The FDA and European Medicines Agency* have warned that taking Actos for longer than one year may be associated with an increased risk of bladder cancer. Regulators in France and Germany have also banned it from being prescribed**.

The resource center discovered as many as 3,000 patients in the U.S. have filed an Actos lawsuit against Takeda Pharmaceuticals over allegations their drug caused bladder cancer***. The first trial began last month in California for Jack Cooper, a grandfather who is terminally ill from the disease***.

Now DrugRisks notes an article from Law360 on March 26, 2013 which quotes the testimony in this case of Dr. Norm D. Smith, an assistant professor of urology and surgery at the University of Chicago, that Actos was the “most substantial causative factor” of Mr. Cooper’s advanced cancer****.

Lawyers continue to help those diagnosed with bladder cancer after taking Actos file claims. Anyone affected is urged to contact the DrugRisks Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of drug injury litigation against large pharmaceutical companies, DrugRisks only recommends lawyers and law firms who have already handled Actos lawsuits.

Visit http://www.DrugRisks.com today for more information on Actos bladder cancer research, side effects and litigation news, or to speak with a lawyer.

*fda.gov/ForConsumers/ConsumerUpdates/ucm263431.htm#Actos; ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/hu an_pha_detail_000033.jsp&mid=WC0b01ac058001d126
**cbsnews.com/8301-504763_162-20070492-10391704.html
***bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html; Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court (Los Angeles).
****Claran McEvoy, "Actos 'Most Substantial" Factor in Man's Cancer, Doc Testifies," March 26, 2013, Law360

Read the full story at http://www.prweb.com/releases/actos-lawsuit-2013/bladder-cancer/prweb10610892.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
2. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
3. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
4. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
5. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
6. Johnson & Johnson Ethicon Transvaginal Mesh Lawsuits Update: Resource4thePeople Reports Judge Schedules More Trials for This Summer
7. DrugRisk Update: Mirena Maker Asks to Keep Lawsuits With Local Court, Judge
8. DrugRisk Update: Bayer Adds Gallbladder Claims to Yaz Settlements
9. Skechers Injury Lawsuit Update: Richard W. Schulte, Partner with Wright & Schulte LLC, Appointed to Plaintiffs’ Steering Committee in California Skechers Toning Shoes Litigation
10. DrugRisk Update: New Pradaxa Study Questions FDA Safety Conclusion
11. Hip Safety Center Update: Patients Ask to Send Stryker Hip Lawsuits to Federal Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: